The utility of genomics and functional imaging to predict Sunitinib pharmacokinetics and pharmacodynamics: The PREDICT SU Study

Trial Profile

The utility of genomics and functional imaging to predict Sunitinib pharmacokinetics and pharmacodynamics: The PREDICT SU Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours; Renal cell carcinoma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
  • Acronyms PREDICT-SU
  • Most Recent Events

    • 24 Jun 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top